03.21.23
Scorpius BioManufacturing, a Texas-based biologics contract research and contract development & manufacturing organization (CDMO), has appointed Gary Welech interim president.
With a career spanning more than 30 years in biopharmaceuticals at large manufacturers like AbbVie and biotech innovators like Agensys and CytomX, Welch will lead Scorpius through its next phase of growth, focused on serving clients working on mammalian & microbial biologics and new modalities.
Jeff Wolf, executive chairman of Scorpius, said, "With extensive experience in process engineering, manufacturing, analytical development, CMC, and site operations, Gary brings a wealth of knowledge to the team. His leadership will help Scorpius to continue on our path to becoming a world-class CDMO."
"I am honored to lead Scorpius as this exciting growth phase continues," Welch said. "We have an extremely experienced team in terms of operating world-class facilities and successfully commercializing biological drugs. Having been on the contract manufacturing side and the innovator side, like many of my colleagues, I understand customers' needs and we are creating an environment where their voices are heard, and we deliver for them."
In April, Scorpius will open new microbial capacity to supplement the mammalian suites at its state-of-the-art facility in San Antonio, Texas, which is focused on clinical-scale production.
The company said that it is committed to building U.S.-based biomanufacturing capacity, with plans to construct a commercial-scale facility in Manhattan, Kansas.
Jeff Wolf, executive chairman of Scorpius, said, "With extensive experience in process engineering, manufacturing, analytical development, CMC, and site operations, Gary brings a wealth of knowledge to the team. His leadership will help Scorpius to continue on our path to becoming a world-class CDMO."
"I am honored to lead Scorpius as this exciting growth phase continues," Welch said. "We have an extremely experienced team in terms of operating world-class facilities and successfully commercializing biological drugs. Having been on the contract manufacturing side and the innovator side, like many of my colleagues, I understand customers' needs and we are creating an environment where their voices are heard, and we deliver for them."
In April, Scorpius will open new microbial capacity to supplement the mammalian suites at its state-of-the-art facility in San Antonio, Texas, which is focused on clinical-scale production.
The company said that it is committed to building U.S.-based biomanufacturing capacity, with plans to construct a commercial-scale facility in Manhattan, Kansas.
